1411774-27-0

Basic information

• Product Name: 3-fluoropyrrolidine-1-sulfonyl chloride
• CAS NO: 1411774-27-0
• Molecular Weight: 187.622
• Mol File: 1411774-27-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-fluoropyrrolidine-1-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoropyrrolidine-1-sulfonyl chloride(1411774-27-0)
• EPA Substance Registry System: 3-fluoropyrrolidine-1-sulfonyl chloride(1411774-27-0)

Safety Data

• Hazardous Substances Data: 1411774-27-0(Hazardous Substances Data)

Upstream product

• 136725-53-6 3-fluoropyrrolidine hydrochloride 
• 136725-53-6 (S)-3-fluoropyrrolidine hydrochloride 
• 136725-53-6 (3R)-3-fluoropyrrolidine hydrochloride 
• 136725-53-6 (R)-3-fluoropyrrolidine hydrochloride salt 

Relevant articles and documents

SMALL MOLECULE MODULATORS KSR-BOUND MEK

An ATP non-competitive inhibitor of mitogen-activated protein kinase (MEK), inter alia, human MEK (MEK1 or MEK2) having the properties: (i) allosterically binds an inhibitor pocket formed at an interaction interface between human MEK (MEKl or MEK2) and human Kinase Suppressor of Ras (KSR1 or KSR2 or BRAE) adjacent to ATP in a physiological complex between MEK and KSR (or BRAE), forming an inhibitor-inhibitor pocket complex; (ii) is an ATP non-competitive kinase inhibitor; (iii) a structure such that when bound to the inhibitor-inhibitor pocket complex, the complex comprises the structural elements:(a) at least one moiety of the inhibitor engaging A825 of KSR1, or P878 of KSR2; or R662 of BRAE (b) at least one moiety engaging R234 of MEK, wherein where R234 is within 5 ? from any atoms of KSR1 or KSR2 or BRAE is disclosed.

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.